CAJ | 학술논문

目的探讨雷珠单抗(Ranibizumab)联合氪激光治疗视网膜分支静脉阻塞(branch retinal vein occlusion,BRVO)继发黄斑水肿的效果.方法 10例(10只眼)BRVO继发黄斑水肿患者接受雷珠单抗玻璃体注射及氪激光局部视网膜光凝,2周、4周后随访,对比治疗前后的最佳矫正视力及黄斑中心凹厚度.结果治疗前最佳矫正视力为0.25 ±0.12,平均黄斑中心凹厚度为(465±123) μm,治疗后2周、4周最佳矫正视力分别为0.32 ±0.16(P =0.031),0.46 ±0.13(P =0.031);2周、4周平均黄斑中心凹厚度为(325 ±89) μm(P =0.040),(285 ±50) μm(P =0.008).结论雷珠单抗联合氪激光治疗视网膜分支静脉阻塞继发黄斑水肿,可以显著提高视力,促进黄斑水肿吸收.
목적 탐토뢰주단항(Ranibizumab)연합극격광치료시망막분지정맥조새(branch retinal vein occlusion,BRVO)계발황반수종적효과.방법 10례(10지안)BRVO계발황반수종환자접수뢰주단항파리체주사급극격광국부시망막광응,2주、4주후수방,대비치료전후적최가교정시력급황반중심요후도.결과 치료전최가교정시력위0.25 ±0.12,평균황반중심요후도위(465±123) μm,치료후2주、4주최가교정시력분별위0.32 ±0.16(P =0.031),0.46 ±0.13(P =0.031);2주、4주평균황반중심요후도위(325 ±89) μm(P =0.040),(285 ±50) μm(P =0.008).결론 뢰주단항연합극격광치료시망막분지정맥조새계발황반수종,가이현저제고시력,촉진황반수종흡수.
Objective To evaluate intravitreal Ranibizumab combined with grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion (BRVO).Methods Ten eyes of 10 patients with macular edema associated with BRVO were included.Intravitreal bevacizumab was administered and then laser photocoagulation was performed 10 days later.The follow up was 2 weeks and 4 weeks.The best-corrected visual acuity(BCVA) and central macular thickness were measured after treatment and compared with baseline BCVA and central macular thickness.Results The mean baseline BCVA was 0.25 ± 0.12,and the mean central macular thickness was (465 ± 123) μm.The mean BCVAs at 2 and 4 weeks after treatment were 0.32 ± 0.16 (P =0.031) and 0.46 ± 0.13 (P =0.031) respectively.The mean central macular thickness at 2 and 4 weeks after treatment were (325 ± 89) μm (P =0.040) and (285 ± 50)μm(P =0.008).Conclusion Intravitreal Ranibizumab combined with grid laser photocoagulation can improve BCVA and alleviate macular edema.